
Product Manual

Cell Contraction Assay

Catalog Number

CBA-201

24 assays

FOR RESEARCH USE ONLY
Not for use in diagnostic procedures



CELL BIOLABS, INC.
Creating Solutions for Life Science Research

Introduction

Wound healing comprises of three processes: epithelialization, connective tissue deposition, and contraction. The contraction process is believed to be mediated by specialized fibroblasts called myofibroblasts. Three-dimensional collagen gels have been widely used in fibroblast contraction studies.


There are several different culture models to study the ability of fibroblasts to reorganize and contract collagen matrices in vitro. In the floating contraction model, a freshly polymerized collagen matrix containing cells is released from the culture dish and allowed to float in culture medium, and contraction occurs in the absence of external mechanical load and without appearance of stress fibers in the cells. In the attached model, a polymerized collagen matrix containing cells remains attached to the culture dish during contraction. Mechanical tension develops during contraction, and cellular stress fibers assemble. The two-step model combines an initial period of attached matrix contraction leading to mechanical loading, followed by release of the matrices, resulting in mechanical unloading and further contraction as mechanical stress dissipates.

The signaling mechanisms used by fibroblasts to regulate collagen matrix contraction depend on whether the cells are mechanically loaded or unloaded at the time that contraction is initiated as well as on the growth factor used to initiate contraction. For instance, stimulation of fibroblasts by lysophosphatidic acid (LPA) but not by platelet-derived growth factor (PDGF) causes robust force generation in restrained matrices, whereas LPA and PDGF stimulate floating matrix contraction equally well.

3D collagen matrix has also been used in the studies of integrin signaling, cell apoptosis and cytoskeleton reorganization. Since three-dimensional matrix adhesions differ in structure, localization, and function from two-dimensional adhesions; and therefore, three-dimensional cell-matrix interactions may be more relevant biologically.

Cell Biolabs' Collagen-based Contraction Assay Kit provides a simple system to assess cell contractivity in vitro and screen cell contraction mediators. Each kit provides sufficient quantities to perform up to 24 assays in a 24-well plate. The kit can also be used for culturing cells in a 3D collagen matrix.

Assay Principle



Kit Components

1. Collagen Solution (Part No. 20101): One 10 mL bottle of sterile bovine Type I Collagen at 3.0 mg/mL
2. Neutralization Solution (Part No. 20102): One 0.5 mL tube
3. 5X DMEM Medium (Part No. 20103): One 5 mL bottle
4. 5X PBS (Part No. 20104): One 5 mL bottle
5. 100X Cell Contraction Inhibitor (Part No. 20105): One 1 mL tube of 1M 2, 3-Butanedione Monoxime (BDM) in DMSO

Materials Not Supplied

1. Cells such as fibroblasts
2. Cell culture medium
3. 37°C Incubator, 5% CO₂ atmosphere
4. Sterile Spatula
5. Light microscope
6. Ruler

Storage

Store all components at 4°C.

Preparation of Collagen Gel Working Solution

This kit is designed for samples in a 24-well plate, and may be modified accordingly to suit other culture plate sizes. Keep all solutions ON ICE the entire time.

Important Note: Be sure to pipet all volumes carefully with well-calibrated pipettes. Volumes of each reagent are critical for collagen polymerization.

1. In a cold sterile tube, add the desired amount of Collagen Solution according to the table below. Next, add 5X DMEM medium or 5X PBS to the tube and mix well.
2. Add Neutralization solution, IMMEDIATELY mix and keep the Collagen Gel Working Solution on ice. *Note: Try to avoid introducing air bubbles to the mixture.*

Reagents	6 wells	12 wells	24 wells
Collagen Solution	2.385 mL	4.77 mL	9.54 mL
5X Medium or PBS	615 µL	1.23 mL	2.46 mL
Neutralization Solution	85 µL	170 µL	340 µL
Total	3.085 mL	6.17 mL	12.34 mL

Assay Protocol (Two-Step Collagen Contraction Model)

1. Harvest cells and resuspend in desired medium at $2-5 \times 10^6$ cells/mL.
2. Prepare the collagen lattice by mixing 2 parts of cell suspension and 8 parts of cold Collagen Gel Working Solution.
Note: Try to avoid introducing air bubbles to the mixture. Carefully mix by titrating the solution. Always include negative control wells that contain no cells in the matrix.
3. Add 0.5 mL of the cell-collagen mixture per well in a 24-well plate, incubate 1 hr at 37°C.
4. After collagen polymerization, 1.0 mL of culture medium is added atop each collagen gel lattice.
5. Cultures are incubated for two days, during which stress develops. Before releasing the stressed matrix, cells may be treated with contraction mediators, such as 10 mM BDM. To initiate contraction, gently release collagen gels from the sides of the culture dishes with a sterile spatula.
6. The collagen gel size change (contraction index) can be measured at various times with a ruler or quantified with image analysis software, such as NIH Image or Image Pro Plus.

Example of Results

The following figure demonstrates typical contraction results using the Cell Contraction Assay. One should use the data below for reference only. This data should not be used to interpret actual results.




Figure 1. Contraction inhibition by BDM. 0.5×10^6 COS-7 cells in 0.5 mL collagen gel lattice were cultured for two days. Before initiation of contraction, cells were pretreated with 10 mM BDM for 1 hr. The change of gel size (diameter) in millimeters was measured with a ruler at various times after release.

References

1. Martin, P. (1997) *Science* **276**, 75-81
2. Bell, E., Ivarsson, B., and Merrill, C. (1979) *Proc. Natl. Acad. Sci. U. S. A.* **76**, 1274-1278
3. Stupak, D., and Harris, A. K. (1982) *Dev. Biol.* **90**, 383-398
4. Mochitate, K., Pawelek, P., and Grinnell, F. (1991) *Exp. Cell Res.* **193**, 198-207
5. Tian, B., Lessan, K., Kahm, J., Kleidon, J., and Henke, C. (2002) *J. Biol. Chem.* **277**, 24667-24675

Recent Product Citations

1. Bharadwaj, A. et al. (2023). Musculoskeletal defects associated with myosin heavy chain-embryonic loss of function are mediated by the YAP signaling pathway. *EMBO Mol Med.* **15**(9):e17187. doi: 10.15252/emmm.202217187.
2. Zhang, H. et al. (2023). Enhanced Cerebral Hemodynamics and Cognitive Function Via Knockout of Dual-Specificity Protein Phosphatase 5. *J Pharm Pharmacol Res.* doi: 10.26502/fjppr.070.
3. Ji, K. et al. (2023). Integrating single-cell RNA sequencing with spatial transcriptomics reveals an immune landscape of human myometrium during labour. *Clin Transl Med.* **13**(4):e1234. doi: 10.1002/ctm2.1234.
4. Li, F.Q. et al. (2023). Bone marrow mesenchymal stem cell-derived exosomal microRNAs target PI3K/Akt signaling pathway to promote the activation of fibroblasts. *World J Stem Cells.* **15**(4):248-267. doi: 10.4252/wjsc.v15.i4.248.
5. Yang, H.M. et al. (2023). Identification of cell-biologic mechanisms of coronary artery spasm and its ex vivo diagnosis using peripheral blood-derived iPSCs. *Biomater Res.* **27**(1):16. doi: 10.1186/s40824-023-00345-2.
6. Zhang, Y. et al. (2022). TIPARP is involved in the regulation of intraocular pressure. *Commun Biol.* **5**(1):1386. doi: 10.1038/s42003-022-04346-0.

7. Ebrahimpour, A. et al. (2022). Combination of esomeprazole and pirfenidone enhances antifibrotic efficacy in vitro and in a mouse model of TGF β -induced lung fibrosis. *Sci Rep.* **12**(1):20668. doi: 10.1038/s41598-022-24985-x.
8. Diao, M. et al. (2022). RAC1 is involved in uterine myometrium contraction in the inflammation-associated preterm birth. *Reproduction.* **164**(4):169-181. doi: 10.1530/REP-21-0186.
9. Zada, A. et al. (2022). The long Filamin-a isoform is required for intestinal development and motility: implications for chronic intestinal pseudo-obstruction. *Hum Mol Genet.* doi: 10.1093/hmg/ddac199.
10. Sheng, F. et al. (2022). Poly amino acid thermosensitive hydrogel loaded with ICG-001 for inhibiting keloid by down-regulating the Wnt/ β -Catenin pathway. *Mater Des.* doi: 10.1016/j.matdes.2022.111050.
11. Böker, V. et al. (2022). Analysis of genomic alterations in cancer associated human pancreatic stellate cells. *Sci Rep.* **12**(1):13532. doi: 10.1038/s41598-022-17748-1.
12. Do, D.V. et al. (2022). The Effects of Irisin on the Interaction between Hepatic Stellate Cell and Macrophage in Liver Fibrosis. *Endocrinol Metab (Seoul).* doi: 10.3803/EnM.2022.1412.
13. Wang, S. et al. (2021). Luseogliflozin, a sodium-glucose co-transporter 2 inhibitor, reverses cerebrovascular dysfunction and cognitive impairments in 18-month-old diabetic animals. *Am J Physiol Heart Circ Physiol.* doi: 10.1152/ajpheart.00438.2021.
14. Wei, Y. et al. (2021). Adrenomedullin ameliorates pulmonary fibrosis by regulating TGF- β -Smads signaling and myofibroblast differentiation. *Endocrinology.* doi: 10.1210/endocr/bqab090.
15. Zou, Q. et al. (2022). Small extracellular vesicles derived from dermal fibroblasts promote fibroblast activity and skin development through carrying miR-218 and ITGBL1. *J Nanobiotechnology.* **20**(1):296. doi: 10.1186/s12951-022-01499-2.
16. Hao, M. et al. (2022). Activation of $\alpha 7$ nicotinic acetylcholine receptor retards the development of endometriosis. *Reprod Biol Endocrinol.* **20**(1):85. doi: 10.1186/s12958-022-00955-w.
17. Wang, S. et al. (2022). Upregulation of GLT25D1 in Hepatic Stellate Cells Promotes Liver Fibrosis via the TGF- β 1/SMAD3 Pathway In Vivo and In vitro. *J Clin Transl Hepatol.* doi: 10.14218/JCTH.2022.00005.
18. Lee, K.W. et al. (2022). PRRX1 is a master transcription factor of stromal fibroblasts for myofibroblastic lineage progression. *Nat Commun.* **13**(1):2793. doi: 10.1038/s41467-022-30484-4.
19. Huang, S. et al. (2022). Tetramethylpyrazine Retards the Progression and Fibrogenesis of Endometriosis. *Reprod Sci.* doi: 10.1007/s43032-021-00813-x.
20. Morales, M.M. et al. (2022). A 2D and 3D cell culture protocol to study O-GlcNAc in sphingosine-1-phosphate mediated fibroblast contraction. *STAR Protoc.* doi: 10.1016/j.xpro.2021.101113.
21. Kim, J.H. et al. (2021). Insulin-activated store-operated Ca²⁺ entry via Orai1 induces podocyte actin remodeling and causes proteinuria. *Nat Commun.* **12**(1):6537. doi: 10.1038/s41467-021-26900-w.
22. Lecce, L. et al. (2021). Histone deacetylase 9 promotes endothelial-mesenchymal transition and an unfavorable atherosclerotic plaque phenotype. *J Clin Invest.* **131**(15):e131178. doi: 10.1172/JCI131178.
23. Xiao, F. et al. (2021). Tumor-Suppressing STF cDNA 3 Overexpression Suppresses Renal Fibrosis by Alleviating Anoikis Resistance and Inhibiting the PI3K/Akt Pathway. *Kidney Blood Press Res.* doi: 10.1159/000517318.
24. Yokota, M. et al. (2021). Staphylococcus aureus impairs dermal fibroblast functions with deleterious effects on wound healing. *FASEB J.* **35**(7):e21695. doi: 10.1096/fj.201902836R.

25. Morales, M.M. et al. (2021). O-GlcNAc modification of MYPT1 modulates lysophosphatidic acid (LPA)-induced cell contraction in fibroblasts. *J Biol Chem*. doi: 10.1016/j.jbc.2021.100800.
26. Zhang, L. et al. (2021). Knockout RAGE alleviates cardiac fibrosis through repressing endothelial-to-mesenchymal transition (EndMT) mediated by autophagy. *Cell Death Dis*. **12**(5):470. doi: 10.1038/s41419-021-03750-4.
27. Liu, P. et al. (2021). Fasudil Dichloroacetate Alleviates SU5416/Hypoxia-Induced Pulmonary Arterial Hypertension by Ameliorating Dysfunction of Pulmonary Arterial Smooth Muscle Cells. *Drug Des Devel Ther*. **15**:1653-1666. doi: 10.2147/DDDT.S297500.
28. Liu, Y. et al. (2021). 20-HETE-promoted cerebral blood flow autoregulation is associated with enhanced pericyte contractility. *Prostaglandins Other Lipid Mediat*. **154**:106548. doi: 10.1016/j.prostaglandins.2021.106548.
29. Kim, G.R. et al. (2021). MicroRNA-212-5p and its target PAFAH1B2 suppress vascular proliferation and contraction via the downregulation of RhoA. *PLoS One*. **16**(3):e0249146. doi: 10.1371/journal.pone.0249146.
30. Uemura, M. et al. (2021). Monophasic Pulsed Current Stimulation of Duty Cycle 10% Promotes Differentiation of Human Dermal Fibroblasts into Myofibroblasts. *Phys Ther Res*. doi: 10.1298/ptr.E10064.

Warranty

These products are warranted to perform as described in their labeling and in Cell Biolabs literature when used in accordance with their instructions. THERE ARE NO WARRANTIES THAT EXTEND BEYOND THIS EXPRESSED WARRANTY AND CELL BIOLABS DISCLAIMS ANY IMPLIED WARRANTY OF MERCHANTABILITY OR WARRANTY OF FITNESS FOR PARTICULAR PURPOSE. CELL BIOLABS' sole obligation and purchaser's exclusive remedy for breach of this warranty shall be, at the option of CELL BIOLABS, to repair or replace the products. In no event shall CELL BIOLABS be liable for any proximate, incidental or consequential damages in connection with the products.

Contact Information

Cell Biolabs, Inc.
7758 Arjons Drive
San Diego, CA 92126
Worldwide: +1 858-271-6500
USA Toll-Free: 1-888-CBL-0505
E-mail: tech@cellbiolabs.com
www.cellbiolabs.com

©2004-2024: Cell Biolabs, Inc. - All rights reserved. No part of these works may be reproduced in any form without permissions in writing.